TP53 缺失通过上调 NF-κB-IFN-β-MHC-Ia 信号促进骨肉瘤对 NK 细胞的抵抗
TP53 Loss Elevates NF-κB-IFN-β-MHC-Ia Signaling to Promote NK Cell Resistance in Osteosarcoma.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
间充质干细胞在肿瘤免疫治疗中的作用
英文原题：The Role of Mesenchymal Stem Cells in Cancer Immunotherapy.
查看英文原题
The Role of Mesenchymal Stem Cells in Cancer Immunotherapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
间充质干细胞（MSCs）在肿瘤免疫治疗领域正受到关注。MSCs对肿瘤的主要作用包括归巢以及调节炎症和免疫反应。事实上，肿瘤免疫治疗已成为一种有前景的治疗方法，而MSCs在调节免疫治疗疗效方面发挥着潜在作用。此外，MSCs是免疫调节蛋白递送的理想载体。因此，MSCs与免疫治疗药物联合可协同抗肿瘤，对肿瘤治疗产生重大影响。MSCs可能在治疗细胞因子风暴或细胞因子释放综合征（CRS）方面具有潜力。据推测，MSCs可以形成嵌合抗原受体MSCs（CAR-MSCs）。CAR-MSCs能否为肿瘤免疫治疗提供新思路尚不清楚。现在是综述MSCs在肿瘤免疫治疗中最新进展的最佳时机，以便在临床实践中阐明并充分理解MSCs在肿瘤治疗中的作用。
展开英文摘要原文
Mesenchymal stem cells (MSCs) are getting attention in the field of cancer immunotherapy. The main effects of MSCs on tumors are homing and regulation of inflammatory and immune responses. Indeed, cancer immunotherapy has become a promising treatment and MSCs play a potential role in regulating the efficacy of immunotherapy.
In addition, MSCs are an ideal carrier for immunomodulatory protein transmission. As such MSCs combined with immunotherapy drugs could act synergistically against tumors, throwing a great impact on cancer therapy. And MSCs may have potential in the treatment of cytokine storm or cytokine release syndrome (CRS).
It is assumed that MSCs can form chimeric antigen receptor MSCs (CAR-MSCs). Whether CAR-MSCs can provide a new idea of cancer immunotherapy is unknown. It is a prime time to review the latest progress of MSCs in cancer immunotherapy, in order to clarify to fully understand the role of MSCs in cancer therapy in clinical practice.
论文信息
- 作者
- Zhao Y、Zhong X、Du F、Wu X、Li M、Wen Q、Shen J、Chen Y
- 单位
- Laboratory of Molecular Pharmacology, School of Pharmacy, Department of Pharmacology, Southwest Medical University, Luzhou, Sichuan, China.China
- 期刊
- Current stem cell research & therapy2023
- 原文标识
- PubMed 36597604 · DOI 10.2174/1574888X18666230103120302